Skip to main content
Erschienen in: PharmacoEconomics 1/2017

01.12.2017 | Review Article

The Use of Mapping to Estimate Health State Utility Values

verfasst von: Roberta Ara, Donna Rowen, Clara Mukuria

Erschienen in: PharmacoEconomics | Sonderheft 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Mapping functions are estimated using regression analyses and are frequently used to predict health state utility values (HSUVs) in decision analytic models. Mapping functions are used when evidence on the required preference-based measure (PBM) is not available, or where modelled values are required for a decision analytic model, for example to control for important sociodemographic variables (such as age or gender). This article provides an overview of the latest recommendations including pre-mapping considerations, the mapping process including data requirements for undertaking the estimation of mapping functions, regression models for estimating mapping functions, assessing performance and reporting standards for mapping studies. Examples in rheumatoid arthritis are used for illustration. When reporting the results of mapping standards the following should be reported: a description of the dataset used (including distributions of variables used) and any analysis used to inform the selection of the model type and model specification. The regression method and specification should be justified, and as summary statistics may mask systematic bias in errors, plots comparing observed and predicted HSUVs. The final model (coefficients, error term(s), variance and covariance) should be reported together with a worked example. It is important to ensure that good practice is followed as any mapping functions will only be as appropriate and accurate as the method used to obtain them; for example, mapping should not be used if there is no overlap between the explanatory and target variables.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Wailoo AJ, Hernandez-Alava M, Manca A, Mejia A, Ray J, Crawford B, et al. Mapping to estimate health-state utility from non-preference-based outcome measures: an ISPOR good practices for outcomes research task force report. Value Health. 2017;20:18–27.CrossRefPubMed Wailoo AJ, Hernandez-Alava M, Manca A, Mejia A, Ray J, Crawford B, et al. Mapping to estimate health-state utility from non-preference-based outcome measures: an ISPOR good practices for outcomes research task force report. Value Health. 2017;20:18–27.CrossRefPubMed
2.
Zurück zum Zitat Longworth L, Rowen D. The use of mapping methods to estimate health state utility values. NICE DSU Technical Support Document 10. 2011. Longworth L, Rowen D. The use of mapping methods to estimate health state utility values. NICE DSU Technical Support Document 10. 2011.
3.
Zurück zum Zitat Ara R, Brazier J, Peasgood T, Paisley S. The identification, review and synthesis of health state utility values from the literature. PharmacoEconomics. 2017. doi:10.1007/s40273-017-0547-8. Ara R, Brazier J, Peasgood T, Paisley S. The identification, review and synthesis of health state utility values from the literature. PharmacoEconomics. 2017. doi:10.​1007/​s40273-017-0547-8.
4.
Zurück zum Zitat Dakin H. Review of studies mapping from quality of life or clinical measures to EQ-5D: an online database. Health Qual Life Outcomes. 2013;11(1):151.CrossRefPubMedPubMedCentral Dakin H. Review of studies mapping from quality of life or clinical measures to EQ-5D: an online database. Health Qual Life Outcomes. 2013;11(1):151.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Longworth L, Rowen D. Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value Health. 2013;16:202–10.CrossRefPubMed Longworth L, Rowen D. Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value Health. 2013;16:202–10.CrossRefPubMed
6.
Zurück zum Zitat Gray AM, Rivero-Arias O, Clarke PM. Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Med Decis Mak. 2006;26(1):18–29.CrossRef Gray AM, Rivero-Arias O, Clarke PM. Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Med Decis Mak. 2006;26(1):18–29.CrossRef
7.
8.
Zurück zum Zitat Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Rheumatology. 1997;36(5):551–9.CrossRef Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Rheumatology. 1997;36(5):551–9.CrossRef
9.
Zurück zum Zitat National Institute for Health and Care Excellence. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. London: NICE; 2010. National Institute for Health and Care Excellence. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. London: NICE; 2010.
10.
Zurück zum Zitat Brazier J, Yang Y, Tsuchiya A, Rowen D. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ. 2010;11(2):215–25.CrossRefPubMed Brazier J, Yang Y, Tsuchiya A, Rowen D. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ. 2010;11(2):215–25.CrossRefPubMed
11.
Zurück zum Zitat Hernandez Alava M, Wailoo AJ, Ara R. Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values. Value in Health. 2012;15(3):550–61.CrossRefPubMed Hernandez Alava M, Wailoo AJ, Ara R. Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values. Value in Health. 2012;15(3):550–61.CrossRefPubMed
12.
Zurück zum Zitat Hernandez Alava M, Wailoo AJ, Wolfe F, Michaud K. The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis. Rheumatology. 2013;52(5):944–50.CrossRefPubMedPubMedCentral Hernandez Alava M, Wailoo AJ, Wolfe F, Michaud K. The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis. Rheumatology. 2013;52(5):944–50.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Petrou S, Rivero-Arias O, Dakin H, Longworth L, Oppe M, Froud R, et al. The MAPS reporting statement for studies mapping onto generic preference-based outcome measures: explanation and elaboration. Pharmacoeconomics. 2015;33(10):993–1011.CrossRefPubMed Petrou S, Rivero-Arias O, Dakin H, Longworth L, Oppe M, Froud R, et al. The MAPS reporting statement for studies mapping onto generic preference-based outcome measures: explanation and elaboration. Pharmacoeconomics. 2015;33(10):993–1011.CrossRefPubMed
14.
Zurück zum Zitat Ara R, Brazier J. Predicting the short form-6D preference-based index using the eight mean short form-36 health dimension scores: estimating preference-based health-related utilities when patient level data are not available. Value Health. 2009;12(2):346–53.CrossRefPubMed Ara R, Brazier J. Predicting the short form-6D preference-based index using the eight mean short form-36 health dimension scores: estimating preference-based health-related utilities when patient level data are not available. Value Health. 2009;12(2):346–53.CrossRefPubMed
15.
Zurück zum Zitat Pennington B, Davis S. Mapping from the Health Assessment Questionnaire to the EQ-5D: the impact of different algorithms on cost-effectiveness results. Value Health. 2014;17(8):762–71.CrossRefPubMed Pennington B, Davis S. Mapping from the Health Assessment Questionnaire to the EQ-5D: the impact of different algorithms on cost-effectiveness results. Value Health. 2014;17(8):762–71.CrossRefPubMed
16.
Zurück zum Zitat Hawthorne G, Buchbinder R, Defina J. Functional status and health-related quality of life assessment in patients with rheumatoid arthritis. Working Paper 116. Centre for Health Program Evaluation. 2000. Hawthorne G, Buchbinder R, Defina J. Functional status and health-related quality of life assessment in patients with rheumatoid arthritis. Working Paper 116. Centre for Health Program Evaluation. 2000.
17.
Zurück zum Zitat Marra CA, Marion SA, Guh DP, Najafzadeh M, Wolfe F, Esdaile JM, et al. Not all quality-adjusted life years are equal. J Clin Epidemiol. 2007;60(6):616–24.CrossRefPubMed Marra CA, Marion SA, Guh DP, Najafzadeh M, Wolfe F, Esdaile JM, et al. Not all quality-adjusted life years are equal. J Clin Epidemiol. 2007;60(6):616–24.CrossRefPubMed
18.
Metadaten
Titel
The Use of Mapping to Estimate Health State Utility Values
verfasst von
Roberta Ara
Donna Rowen
Clara Mukuria
Publikationsdatum
01.12.2017
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe Sonderheft 1/2017
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-017-0548-7

Weitere Artikel der Sonderheft 1/2017

PharmacoEconomics 1/2017 Zur Ausgabe